Silence Therapeutics plc
SLNCF
$1.80
$0.2012.50%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -29.02% | 57.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -29.02% | 57.75% | |||
| Cost of Revenue | -24.71% | 57.41% | |||
| Gross Profit | -31.65% | 57.95% | |||
| SG&A Expenses | 12.94% | -33.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.24% | -20.79% | |||
| Operating Income | -16.74% | 21.23% | |||
| Income Before Tax | 23.36% | 4.16% | |||
| Income Tax Expenses | -90.00% | -- | |||
| Earnings from Continuing Operations | 23.38% | 4.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.38% | 4.12% | |||
| EBIT | -16.74% | 21.23% | |||
| EBITDA | -16.82% | 21.38% | |||
| EPS Basic | 22.29% | 4.14% | |||
| Normalized Basic EPS | 18.33% | 8.82% | |||
| EPS Diluted | 22.29% | 4.14% | |||
| Normalized Diluted EPS | 18.33% | 8.82% | |||
| Average Basic Shares Outstanding | -1.39% | 0.01% | |||
| Average Diluted Shares Outstanding | -1.39% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||